| 2023 | Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
| DIAGNOSTICS |
| 2016 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
| PLOS ONE |
| 2021 | Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
| ONCOLOGIST |
| 2006 | Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin | HUMAN GENE THERAPY |
| 2017 | Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
| JOURNAL OF BREAST CANCER |
| 2012 | Metaplastic breast cancer: clinicopathological features and its prognosis | JOURNAL OF CLINICAL PATHOLOGY |
| 2022 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
| CANCERS |
| 2011 | Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer | ONCOLOGY |
| 2021 | Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
| PHARMACEUTICALS |
| 2017 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2017 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2007 | Multi-disciplinary treatment of a rare pelvic cavity ependymoma
| YONSEI MEDICAL JOURNAL |
| 2013 | Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
| ANNALS OF ONCOLOGY |
| 2020 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial | LANCET |
| 2017 | Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
| ANNALS OF SURGICAL TREATMENT AND RESEARCH |
| 2020 | Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
| SCIENTIFIC REPORTS |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 2003 | Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2006 | Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer | ONCOLOGY REPORTS |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2023 | Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2014 | Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer | CANCER |
| 2020 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study | ANNALS OF ONCOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2009 | Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma | ONCOLOGY |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2007 | Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
| CANCER |
| 2017 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) | ESMO OPEN |
| 2012 | Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram
| NEURO-ONCOLOGY |
| 2015 | Prediction of short- and long-term survival for advanced cancer patients after ICU admission | SUPPORTIVE CARE IN CANCER |
| 2016 | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | BREAST |
| 2020 | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
| CANCER RESEARCH AND TREATMENT |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2019 | Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
| CANCER RESEARCH AND TREATMENT |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Regarding the article by Rugo Reply
| ONCOLOGIST |
| 2021 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs | Clinical and Translational Science |
| 2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
| JAMA ONCOLOGY |
| 2007 | Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells | JOURNAL OF CONTROLLED RELEASE |
| 2023 | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
| ESMO OPEN |
| 2021 | Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective | ANNALS OF SURGERY |
| 2008 | Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| BMC CANCER |
| 2021 | Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
| BRITISH JOURNAL OF CANCER |
| 2009 | Sonographic surveillance for the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2001 | Squamous Cell Carcinoma of the Cornea
| YONSEI MEDICAL JOURNAL |
| 2021 | Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
| CANCER RESEARCH AND TREATMENT |
| 2023 | Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
| JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
| 2023 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2018 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control | CANCER NURSING |
